世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の女性用避妊具市場 2018-2022年

Global Female Contraceptive Market 2018-2022

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年2月US$2,500
シングルユーザライセンス
136

サマリー

このレポートは世界の女性用避妊具市場を調査したTechNavioの調査報告書です。

Report Details

About Female Contraceptive
Female contraceptives are used by women for family planning and to avoid unintended pregnancies.
Technavio’s analysts forecast the global female contraceptive market to grow at a CAGR of 3.44 % during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the global female contraceptive market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of female contraceptive.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, Global Female Contraceptive Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Allergan
- Bayer
- Lupin Pharmaceuticals
- Merck
- Pfizer
- Foundation Consumer Healthcare


Market driver
- Evolving consumer perspective
- For a full, detailed list, view our report

Market challenge
- Irregularities in sex education in developed countries
- For a full, detailed list, view our report

Market trend
- Increase in use of female condoms
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?


You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.





目次

Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
- Overview
- Comparison by product
- Female contraceptive devices
- Female contraceptive drugs
- Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Female contraceptive market in Americas
- Female contraceptive market in EMEA
- Female contraceptive market in APAC
- Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 12: MARKET TRENDS
- Increase in use of female condoms
- High disposable income in US
- Advent of smart condoms
PART 13: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 14: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Allergan
- Bayer1
- Lupin Pharmaceuticals
- Merck
- Pfizer
- Foundation Consumer Healthcare
- Other prominent vendors
PART 15: APPENDIX
- List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global contraceptive market: Segments
Exhibit 03: Market characteristics
Exhibit 04: Global female contraceptive market: Segments
Exhibit 05: Advantages and disadvantages of different types of contraceptives
Exhibit 06: Market definition: Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global female contraceptive market 2017-2022 ($ millions)
Exhibit 10: Global female contraceptive market: Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition: Five forces 2017
Exhibit 19: Global female contraceptive market: Segmentation by product 2017-2022 (% share)
Exhibit 20: Types of female contraceptive devices and drugs
Exhibit 21: Comparison by product
Exhibit 22: Global female contraceptive devices market 2017-2022 ($ millions)
Exhibit 23: Global female contraceptive devices market: Year-over-year growth 2018-2022 (%)
Exhibit 24: Global IUDs market 2017-2022 ($ millions)
Exhibit 25: Global female sterilization market 2017-2022 ($ millions)
Exhibit 26: Global subdermal contraceptive implants market 2017-2022 ($ millions)
Exhibit 27: Global vaginal rings market 2017-2022 ($ millions)
Exhibit 28: Global female condoms market 2017-2022 ($ millions)
Exhibit 29: Global nonsurgical permanent contraception market 2017-2022 ($ millions)
Exhibit 30: Global contraceptive diaphragms market 2017-2022 ($ millions)
Exhibit 31: Global contraceptive sponges market 2017-2022 ($ millions)
Exhibit 32: Global female contraceptive drugs market 2017-2022 ($ millions)
Exhibit 33: Global female contraceptive drugs market: Year-over-year growth 2018-2022 (%)
Exhibit 34: Global birth control pills market 2017-2022 ($ millions)
Exhibit 35: Global emergency contraceptive pills market 2017-2022 ($ millions)
Exhibit 36: Market opportunity by product
Exhibit 37: Customer landscape
Exhibit 38: Global female contraceptive market: Segmentation by geography 2017-2022 (% share)
Exhibit 39: Regional comparison
Exhibit 40: Female contraceptive market in Americas 2017-2022 ($ millions)
Exhibit 41: Female contraceptive market in Americas: Year-over-year growth 2018-2022 (%)
Exhibit 42: Top-three countries in Americas
Exhibit 43: Female contraceptive market in EMEA 2017-2022 ($ millions)
Exhibit 44: Female contraceptive market in EMEA: Year-over-year growth 2018-2022 (%)
Exhibit 45: Top-three countries in EMEA
Exhibit 46: Female contraceptive market in APAC 2017-2022 ($ millions)
Exhibit 47: Female contraceptive market in APAC: Year-over-year growth 2018-2022 (%)
Exhibit 48: Top-three countries in APAC
Exhibit 49: Market opportunity
Exhibit 50: State-wise disposable income in US 2015
Exhibit 51: Vendor landscape
Exhibit 52: Landscape disruption
Exhibit 53: Vendors covered
Exhibit 54: Vendors covered
Exhibit 55: Vendor classification
Exhibit 56: Market positioning of vendors
Exhibit 57: Allergan: Overview
Exhibit 58: Allergan: Business segments
Exhibit 59: Allergan: Organizational developments
Exhibit 60: Allergan: Geographic focus
Exhibit 61: Allergan: Segment focus
Exhibit 62: Allergan: Key offerings
Exhibit 63: Bayer: Overview
Exhibit 64: Bayer: Business segments
Exhibit 65: Bayer: Organizational developments
Exhibit 66: Bayer AG: Geographic focus
Exhibit 67: Bayer: Segment focus
Exhibit 68: Bayer: Key offerings
Exhibit 69: Lupin Pharmaceuticals: Overview
Exhibit 70: Lupin Pharmaceuticals: Business segments
Exhibit 71: Lupin Pharmaceuticals: Organizational developments
Exhibit 72: Lupin Pharmaceuticals: Geographic focus
Exhibit 73: Lupin Pharmaceuticals: Segment focus
Exhibit 74: Lupin Pharmaceuticals: Key offerings
Exhibit 75: Merck: Overview
Exhibit 76: Merck: Business segments
Exhibit 77: Merck: Organizational developments
Exhibit 78: Merck: Geographic focus
Exhibit 79: Merck: Segment focus
Exhibit 80: Merck: Key offerings
Exhibit 81: Pfizer: Overview
Exhibit 82: Pfizer: Business segments
Exhibit 83: Pfizer: Organizational development
Exhibit 84: Pfizer: Geographic focus
Exhibit 85: Pfizer: Segment focus
Exhibit 86: Pfizer: Key offerings
Exhibit 87: Foundation Consumer Healthcare: Overview
Exhibit 88: Foundation Consumer Healthcare: Business segments
Exhibit 89: Foundation Consumer Healthcare: Organizational developments
Exhibit 90: Foundation Consumer Healthcare: Geographic focus
Exhibit 91: Foundation Consumer Healthcare: Segment focus
Exhibit 92: Foundation Consumer Healthcare: Key offerings

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る